These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7695958)

  • 1. Evaluation of haematopoietic growth factors: defining relevant clinical endpoints in growth factor trials.
    Linch DC
    Eur J Cancer; 1994; 30A Suppl 3():S40-3. PubMed ID: 7695958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost implications of haematopoietic growth factors in the BMT setting.
    Petros WP; Peters WP
    Bone Marrow Transplant; 1993; 11 Suppl 2():36-8. PubMed ID: 8334436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas.
    Liem GS; Verweij J
    Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of hematopoietic growth factors in bronchial cancerology].
    Lemarié E; Milleron B
    Rev Mal Respir; 1995; 12(5):429-34. PubMed ID: 8560073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical consequences of haematological and non-haematological toxicity following bone marrow transplantation and the possible impact of haematopoietic growth factors.
    Maraninchi D
    Bone Marrow Transplant; 1993; 11 Suppl 2():12-22. PubMed ID: 8334434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The present and future of hematopoietic cytokines in clinical practice.
    George MJ
    Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future use of hematopoietic growth factors in cancer medicine.
    Mughal TI
    Hematol Oncol; 2004 Sep; 22(3):121-34. PubMed ID: 15991222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hematopoietic growth factors in the treatment of acute myeloblastic leukemia].
    de la Rubia Comos J
    Sangre (Barc); 1997 Apr; 42 Suppl 1():32-3. PubMed ID: 9381298
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hematopoietic growth factors in oncology and hematology. Recommendations for more cost-efficient use].
    Paul C; Hast R
    Lakartidningen; 2000 Jun; 97(23):2862-6. PubMed ID: 10885223
    [No Abstract]   [Full Text] [Related]  

  • 14. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors.
    Chao NJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():43-6. PubMed ID: 8853524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
    Marsh JC; Ganser A; Stadler M
    Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
    Grossi F; Tiseo M
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
    Wingard JR; Elmongy M
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.